# US 2023/0272433 A1 · Enhancing Utrophin Expression in Cell by Inducing Mutations Within Utrophin Regulatory Elements and Therapeutic Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272433 A1
- Document ID: US20230272433A1
- Status: Published application
- Kind: A1
- Application number: 18/024,102
- Filed: 2021-09-29
- Published: 2023-08-31
- Earliest claimed: 2020-09-29
- Assignees: Genethon; Universite D'Evry Val D'Essonne; Institut National de la Sante et de la Recherche Medicale
- Applicants: Genethon; Universite d'Evry Val d'Essonne; Inserm( Institut National De La Santé Et De La Recherche MéDicale)
- Inventors: Mario Amendola; Simon Guiraud
- Web page: https://patentgrep.com/patent/US20230272433A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/907: {in mammalian cells}
- C12N 5/0658: {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to a composition for enhancing utrophin expression in cell by inducing mutations within a target sequence comprising a utrophin repressor binding site using a gene editing enzyme and the use thereof for the treatment of a dy-strophinopathy.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method for enhancing utrophin expression in a cell, comprising introducing into a cell a composition comprising at least one gene editing enzyme capable of inducing site-specific mutation(s) within a target sequence comprising at least one repressor binding site of utrophin gene selected from the group consisting of: Ets-2-repressor factor (ERF) binding sites, homeobox protein engrailed-1 (EN1) binding site 2, Let7c binding site and miR-196b binding site, wherein said mutation(s) disrupt the repressor binding site without deleting the whole repressor binding site sequence.

### Claim 20 (depends on 19)

The method of claim 19, wherein said repressor binding site is selected from the group consisting of ERF binding site consisting of sequence CGGAA, EN1 binding site 2 consisting of sequence GTAGTGG, Let7c binding site consisting of SEQ ID NO: 1, and miR-196b binding site consisting of sequence SEQ ID NO: 2.

### Claim 21 (depends on 19)

The method of claim 19, wherein said repressor binding site is Let7c binding site.

### Claim 22 (depends on 19)

The method of claim 19, wherein said gene editing enzyme is selected from the group consisting of a site-specific nuclease, base editor and prime editor.

### Claim 23 (depends on 22)

The method of claim 22, wherein said gene editing enzyme is a CRISPR/Cas gene editing enzyme comprising a guide RNA that comprises a complementary sequence to said target sequence comprising a utrophin repressor binding site.

### Claim 24 (depends on 22)

The method according to claim 22, wherein said gene editing enzyme is a CRISPR/Cas gene editing enzyme comprising a guide RNA selected from the group consisting of SEQ ID NO: 3 to 17 and 25.

### Claim 25 (depends on 19)

The method according to claim 19, wherein said composition comprises at least two gene editing enzymes which are sequence-specific nucleases and wherein said nucleases are used successively in such a way that a first sequence-specific nuclease induces a first site-specific mutation event within a target sequence and once first mutation event is repaired, a second sequence-specific nuclease is used to induce a second site-specific mutation event within a target sequence.

### Claim 26

A composition for enhancing utrophin expression comprising at least one gene editing enzyme capable of inducing site-specific mutation within a target sequence comprising a repressor binding site of utrophin gene selected from the group consisting of: Ets-2-repressor factor (ERF) binding sites consisting of sequence CGGAA, homeobox protein engrailed-1 (EN1) binding site 2 consisting of sequence GTAGTGG, Let7c binding site consisting of SEQ ID NO: 1 and miR-196b binding site consisting of SEQ ID NO: 2 and wherein the mutation(s) disrupt the repressor binding site without deleting the whole repressor binding site sequences.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the repressor binding site of utrophin gene is Let7c binding site consisting of SEQ ID NO: 1.

### Claim 28 (depends on 27)

The composition of claim 27 wherein said gene editing enzyme is CRISPR/Cas gene editing enzyme comprising a guide RNA that comprises a complementary sequence to said target sequence comprising a utrophin repressor binding site.

### Claim 29 (depends on 27)

The composition of claim 27, wherein said gene editing enzyme is a CRISPR/Cas gene editing enzyme comprising guide RNA comprising a sequence selected from the group consisting of SEQ ID NO: 3 to 17 and 25.

### Claim 30 (depends on 26)

The composition according to claim 26, wherein said gene editing enzyme is encoded by a nucleic acid construct.

### Claim 31 (depends on 30)

The composition according to claim 30, wherein said nucleic acid construct is included in a viral vector.

### Claim 32 (depends on 30)

The composition according to claim 30, wherein said nucleic acid construct is included in an AAV vector.

### Claim 33 (depends on 26)

The composition according to claim 26 which is a pharmaceutical composition, further comprising a pharmaceutical excipient.

### Claim 34 (depends on 26)

The composition according to claim 26 which is a pharmaceutical composition for treating dystrophinopathies.

### Claim 35 (depends on 26)

The composition according to claim 26 which is a pharmaceutical composition for treating a dystrophinopathy selected from the group consisting of: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and X-linked dilated cardiomyopathy.

### Claim 36

An engineered cell comprising site-specific mutation(s) within at least one target sequence comprising repressor binding site of utrophin gene selected from the group consisting of: Ets-2-repressor factor (ERF) binding sites, homeobox protein engrailed-1 (EN1) binding site 2, Let7c binding site and miR-196b binding site, wherein the mutations disrupt repressor binding site without deleting the whole repressor binding site sequence.

### Claim 37 (depends on 36)

The engineered cell of claim 36, wherein said Ets-2-repressor factor (ERF) binding sites consists of sequence CGGAA, homeobox protein engrailed-1 (EN1) binding site 2 consists of sequence GTAGTGG, Let7c binding site consists of SEQ ID NO: 1 and miR-196b consists of SEQ ID NO: 2.

### Claim 38 (depends on 36)

The engineered cell of claim 36, wherein said repressor binding site of utrophin gene is Let7c binding site.
